Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

被引:158
作者
Mohty, M
Bay, JO
Faucher, C
Choufi, B
Bilger, K
Tournilhac, O
Vey, N
Stoppa, AM
Coso, D
Chabannon, C
Viens, P
Maraninchi, D
Blaise, D
机构
[1] Inst J Paoli I Calmettes, Unite Transplantat & Therapie Cellulaire, F-13273 Marseille 09, France
[2] Ctr Jean Perrin, Ctr Transplantat Medullaire, Clermont Ferrand, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13273 Marseille, France
[4] Univ Mediterranee, F-13273 Marseille 09, France
[5] Inst J Paoli I Calmettes, Ctr Therapie Cellulaire & Gen, F-13273 Marseille 09, France
[6] Inst J Paoli I Calmettes, Dept Med Oncol, F-13273 Marseille 09, France
关键词
D O I
10.1182/blood-2002-12-3629
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced-intensity conditioning (RIC) regimens are increasingly used for allogeneic stem cell transplantation (allo-SCT). RIC has been shown to allow engraftment with minimal early transplantation-related mortality (TRM). However, in the context of RIC, predictive factors for acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) and their effect on outcome remain unknown. In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG). The cumulative incidence of grade II-IV aGVHD was 36% (95% confidence interval [CI], 27%-45%), whereas the cumulative incidence of cGVHD at 2 years was 43% (95% CI, 33%-53%). In multivariate analysis, the incidence of aGVHD was significantly associated with the ATG dose infused during conditioning (P=.0005), whereas peripheral blood as stem cell source was the only predictive factor for the development of cGVHD (P=.0007). The 1-year cumulative incidences of disease progression or relapse in patients with (n=69) and without (n=31) GVHD (whatever its form or grade) were 30% (95% CI, 19%-41%) and 55% (95% CI, 37%-72%), respectively (P=.02), suggesting that a potent graft-versus-tumor (GVT) effect can be achieved in high-risk patients following RIC. Moreover, the GVT effect was closely associated with GVHD without an increased risk of TRM (cumulative incidence of TRM, 18% [95% CI, 10%-25%]). Collectively, these results provide a framework for the refinement of RIC approaches designed to enhance the GVT effect with an acceptable risk of GVHD. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:470 / 476
页数:7
相关论文
共 54 条
[1]  
APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53
[2]   SUCCESSFUL ALLOGENEIC TRANSPLANTATION OF T-CELL DEPLETED BONE-MARROW FROM CLOSELY HLA-MATCHED UNRELATED DONORS [J].
ASH, RC ;
CASPER, JT ;
CHITAMBAR, CR ;
HANSEN, R ;
BUNIN, N ;
TRUITT, RL ;
LAWTON, C ;
MURRAY, K ;
HUNTER, J ;
BAXTERLOWE, LA ;
GOTTSCHALL, JL ;
OLDHAM, K ;
ANDERSON, T ;
CAMITTA, B ;
MENITOVE, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (08) :485-494
[3]  
ATKINSON K, 1990, BLOOD, V75, P2459
[4]  
ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P69
[5]   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [J].
Bensinger, WI ;
Martin, PJ ;
Storer, B ;
Clift, R ;
Forman, SJ ;
Negrin, R ;
Kashyap, A ;
Flowers, MED ;
Lilleby, K ;
Chauncey, TR ;
Storb, R ;
Appelbaum, FR ;
Rowley, S ;
Heimfeld, S ;
Blume, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :175-181
[6]   Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies:: a pilot study [J].
Blaise, D ;
Jourdan, E ;
Michallet, M ;
Jouet, JP ;
Boiron, JM ;
Michel, G ;
Faucher, C ;
Fégueux, N ;
Schuller, MP ;
Badri, N ;
Chabannon, C ;
Maraninchi, D .
BONE MARROW TRANSPLANTATION, 1998, 22 (12) :1153-1158
[7]   Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle [J].
Blaise, D ;
Kuentz, M ;
Fortanier, C ;
Bourhis, JH ;
Milpied, N ;
Sutton, L ;
Jouet, JP ;
Attal, M ;
Bordigoni, P ;
Cahn, JY ;
Boiron, JM ;
Schuller, MP ;
Moatti, JP ;
Michalle, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :537-546
[8]   Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality [J].
Brown, RA ;
Adkins, D ;
Khoury, H ;
Vij, R ;
Goodnough, LT ;
Shenoy, S ;
DiPersio, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :806-812
[9]  
BUNJES D, 1995, BONE MARROW TRANSPL, V15, P563
[10]   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].
Carella, AM ;
Cavaliere, M ;
Lerma, E ;
Ferrara, R ;
Tedeschi, L ;
Romanelli, A ;
Vinci, M ;
Pinotti, G ;
Lambelet, P ;
Loni, C ;
Verdiani, S ;
De Stefano, F ;
Valbonesi, M ;
Corsetti, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924